SPC/GB21/069 WAS ADDED TO THE JOURNAL 7041 INCORRECTLY IDENTIFYING THE INCORRECT MAXIMUM EXPIRY DATE ON WHICH THE SPC IS BASED. PLEASE SEE THE UPDATED JOURNAL ENTRY.; APPLICANT: INTELLIKINE, LLC; 10931 NORTH TORREY PINES ROAD, LA JOLLA CA 92037, UNITED STATES OF AMERICA; PRODUCT: DUVELISIB; PRODUCT TYPE: MEDICINAL; AUTHORISED:; EU/1/21/1542/001 21 MAY 2021 (NI); EU/1/21/1542/002 21 MAY 2021 (NI) ; FURTHER MA'S ON IPSUM; ; AUTHORISED EXTENSION:; PATENT NO: EP2456444; TITLE: ADENINE DERIVATIVE AS PI3K INHIBITOR; SPC NO: SPC/GB21/069; DATE GRANTED: 05 APRIL 2024; MAXIMUM PERIOD EXPIRES ON: 14 JULY 2035; CORRECTED DATA
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
